BiVictriX Therapeutics PLC Patent Granted in Japan (4521T)
2023年11月15日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMBVX
RNS Number : 4521T
BiVictriX Therapeutics PLC
15 November 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Patent Granted in Japan Providing Further Broad Protection for
BVX001
-- Provides broad protection for lead product, BVX001, in a
market where AML is the most common acute leukaemia, accounting for
c.70% of all myeloid leukaemias
-- Builds upon the recent US patent grant, providing strong IP
position in two key global markets
-- Prosecution for the patent family currently being pursued in
a further six global jurisdictions
Alderley Park, 15 November 2023 - BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a
differentiated approach to develop novel, next-generation
anti-cancer precision Antibody Drug Conjugates, offering
substantially improved cancer cell selectivity and therapeutic
activity, announces today that the Japanese Patent Office ("JPO")
has granted a patent providing broad protection for the Company's
lead asset, BVX001.
This follows the Company's announcement on 23 August 2023
regarding the grant by the United States Patent and Trademark
Office. This latest patent grant from the JPO is part of the
Company's strategy of broad protection for BVX001. The claims
granted within this patent (patent number 7337824), which belongs
to the wider patent family "Therapy", are currently being
prosecuted in a further six jurisdictions worldwide to provide
ultimate broad protection for BVX001 at the highest antigen
level.
Tiffany Thorn, CEO of BiVictriX commented: "The approval of this
patent in Japan, which follows swiftly after the granting of our
patent in the US, puts BiVictriX in a strong IP position in two key
global markets. With plans to prosecute in a further six global
jurisdictions, we are building strong protection for our lead
therapeutic asset, at the broadest level, enhancing the value of
BVX001 as we prepare for first in human studies and refine the
optimal drug development and commercialisation strategy ."
ENDS
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Email: info@bivictrix.com
Chairman
SP Angel Corporate Finance LLP Tel: +44 (0) 20 3470 0470
(NOMAD and Broker)
David Hignell, Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre, Rob Rees (Sales
and Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886 2500
Broker)
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR Consilium
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Max Bennett, Emmalee Hoppe Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a new
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst significantly reducing
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) Antibody Drug Conjugate
therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "Bi-Cygni(R) fingerprints", on
tumour cells, which are largely absent from healthy cells.
BiVictriX has established a growing proprietary library of
cancer-specific Bi-Cygni(R) fingerprints, which enable the Company
to target a diverse array of different cancer types. The Company
utilises these novel Bi-Cygni(R) fingerprints, together with the
Company's novel Antibody Drug Conjugate therapeutic design, to
develop more effective and safer therapeutics to target cancers
that are expected to constitute orphan indications and areas of
high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFVDLVLSLIV
(END) Dow Jones Newswires
November 15, 2023 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
過去 株価チャート
から 3 2024 まで 4 2024
Bivictrix Therapeutics (LSE:BVX)
過去 株価チャート
から 4 2023 まで 4 2024